At Shape, we're pioneering a breakthrough in healthcare with proprietary engineered SHAPEnano particles, leveraging the immune system of patients to produce therapeutic antibodies directly inside their bodies. Our game-changing approach offers unparalleled advantages over traditional antibodies: just 2-3 doses yearly, no anti-drug antibodies, and substantial cost savings. With millions of underserved patients in multi-billion-dollar markets, each Shape product holds blockbuster potential. Our founders bring a wealth of R&D, manufacturing, and business acumen as repeat founders, and from biotech startups to Pharma giants. By merging expertise in immunobiology, chemistry, and medicine with cutting-edge computational design, we're creating novel immunotherapies with transformative impact.
Shape Biopharmaceuticals wins Venture Kick finale (startupticker.ch)
Venture Leaders Biotech scale new heights in Boston (venturelab.swiss)
Shape Biopharmaceuticals: The Venture Leader Biotech shaping the future of immunotherapy (venturelab.swiss)
CHF 40,000 for video consumption with AI, next-gen immunotherapy, and advanced recycling solutions (venturekick.ch)
The road to Boston: Venture Leaders Biotech 2024 kick-off their roadshow at Swiss Biotech Day (venturelab.swiss)
Ten startups on a business voyage in Boston (startupticker.ch)
Venture Leaders Biotech 2024: 10 innovative startups selected for the Boston roadshow (venturelab.swiss)